NEW YORK and and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted an equity award on March 2, 2024, to a newly-hired, non-executive employee. The inducement grant was approved by the Company's independent Compensation Committee and was made as a material inducement to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grant consists of a non-qualified stock option to purchase an aggregate of 30,000 shares of the Company's common stock with a 10-year term and an exercise price of $25.75 per share. The option vests as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grant is subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of the Stock Option Agreement.

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.  

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
This email address is being protected from spambots. You need JavaScript enabled to view it.